reports
- MarketLine Department
Sagent Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnersh...
Summary Marketline's Sagent Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Sagent Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive brea...
- MarketLine Department
Mallinckrodt Plc - Mergers & Acquisitions (M&A), Partnerships & Allian...
Summary Marketline's Mallinckrodt Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Mallinckrodt Plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and...
- Dominic Rose
- Naresh Chouhan
Revenue Downgrade Cycle Almost Over
Persistent revenue downgrades have led to investor concern around future analyst forecasts, particularly for new drugs. Our analysis shows that the causes of the sector revenue downgrades have been largely driven by Primary Care launches in the US. More importantly, we show that the downside risk to future new product forecasts has fallen materially. We argue that if forecasts are now more accurate, the recent Pharma sell-off creates a good entry point.
- Damien Conover
Trump’s Blueprint to Lower Drug Prices Offers Minor Changes; No Big ...
The Trump administration’s policy paper titled “The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs†offers proposals that don’t impact our moat ratings in the Big Pharma and Biotech industries, and the pricing power of branded drugs in the U.S. still looks strong. The blueprint’s near-term focus largely supports increasing generic drug competition, slightly strengthening Medicare drug price negotiations, improving drug price transparency, and providi...
- Damien Conover
Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big P...
Trump’s policy speech on lowering drug prices didn’t offer many specifics and focused mostly on reducing middleman profits and raising drug prices overseas. Based on the 2019 U.S. government budget proposal and the Council of Economic Advisors white paper on drug policy, we expect only modest negative headwinds to branded drug prices. We continue to view moats within Big Pharma/Biotech industries as intact, supported by strong pricing power for patent protected drugs. We view the branded dru...
- Damien Conover
Cost-saving plans and recent product launches should offset patent los...
Pfizer reported first-quarter results slightly below both our and consensus top-line expectations, but we don’t expect any major changes to our $43.50 fair value estimate. We continue to view the stock as undervalued, partly due to an underappreciation for Pfizer’s overall growth potential and growing strength in oncology led by Ibrance. We continue to view the company with a wide moat, supported by one of the widest portfolios of patent protected drugs in the Big Pharma industry. In the qua...
- Louis AZAIS
- Louis AZAIS
- Damien Conover
Generic Pressure, Manufacturing, and Order Timing Weigh on Pfizer’s ...
Pfizer reported first-quarter results slightly below both our and consensus top-line expectations, but we don’t expect any major changes to our $43.50 fair value estimate. We continue to view the stock as undervalued, partly due to an underappreciation for Pfizer’s overall growth potential and growing strength in oncology led by Ibrance. We continue to view the company with a wide moat, supported by one of the widest portfolios of patent protected drugs in the Big Pharma industry. In the qua...
- Louis AZAIS
Short term view - PFIZER INC : The support has been reached, it causes...
The trend is still bullish, the invalidation level is below $34.30. The target is at $39.07.Arguments :- The support has been reached, it causes the bounce.- Prices are breaking above the moving average, it is a sign of strength.
- Louis AZAIS
Analyse court terme - PFIZER INC : Le support est atteint, il cause le...
La tendance est toujours haussière, son niveau d'invalidation est sous 34,30 $. L'objectif est à 39,07 $.Arguments :- Le support est atteint, il cause le rebond.- Les prix dépassent la moyenne mobile, c'est un signal de force.
- Louis AZAIS
Short term view - PFIZER INC : The moving average is supporting prices...
The trend is still bullish, the invalidation level is below $33.500. The target is at $39.070.Arguments :- The major support has been reached, it causes the bounce.- The resistance has been reached, it causes the fall.- The moving average is supporting prices.
- Louis AZAIS
Analyse court terme - PFIZER INC : La moyenne mobile sert de support.
La tendance est toujours haussière, son niveau d'invalidation est sous 33,500 $. L'objectif est à 39,070 $.Arguments :- Le support majeur est atteint, il cause le rebond.- La résistance est atteinte, elle cause le repli.- La moyenne mobile sert de support.
- Dominic Rose
- Naresh Chouhan
- Tansy Billingham
Pfizer to Join OTC JV
GSK is down to the last two in the bidding for the Pfizer OTC business. We believe that a 3-way JV (PFE/GSK/NOVN) would suit all parties and show that the deal would be EPS and NPV accretive to all. We also show that there is significant complementarity across the 2 portfolios which would create a business which has double the market share of the next biggest OTC player. This structure would mean PFE has no EPS dilution from a divestment, GSK keeps firepower for Pharma & Novartis increases in va...
- Louis AZAIS
Short term view - PFIZER INC : Prices are breaking above the moving av...
The trend is still bullish, the invalidation level is below $33.50. The target is at $39.07.Arguments :- The major support has been shortly breached, but it is now reinstated. Prices can bounce.- Prices are breaking above the moving average, it is a sign of strength.
- Louis AZAIS
Analyse court terme - PFIZER INC : Les prix dépassent la moyenne mobi...
La tendance est toujours haussière, son niveau d'invalidation est sous 33,50 $. L'objectif est à 39,07 $.Arguments :- Le support majeur a été enfoncé, mais il est réintégré. Les prix peuvent rebondir.- Les prix dépassent la moyenne mobile, c'est un signal de force.
- Louis AZAIS
Medium term view - PFIZER INC : Pull-back over
The trend is still bullish, the invalidation level is below $33.40. The target is at $40.80.Arguments :- The support has been reached, it causes the bounce.- Prices have pulled back to the major support level (previously a resistance). The rise is now resuming.- The moving average is supporting prices.
- Louis AZAIS
Analyse moyen terme - PFIZER INC : Pull-back achevé
La tendance est toujours haussière, son niveau d'invalidation est sous 33,40 $. L'objectif est à 40,80 $.Arguments :- Le support est atteint, il cause le rebond.- Les cours ont fait un pull-back sur le support majeur (ancienne résistance), la hausse reprend.- La moyenne mobile sert de support.
- Damien Conover
Cost-saving plans and recent product launches should offset patent los...
Pfizer reported slightly higher-than-expected fourth-quarter results and issued 2018 tax-rate guidance 500 basis points below our expectations, which will likely lead to an increase in our fair value estimate relatively close to the current stock price. Pfizer’s largely flat total revenue in the quarter despite generic competition, combined with the likelihood it can retain most of the U.S. tax reform benefits, helps reinforce our wide moat rating for the firm. Pfizer’s core drugs (pneumoco...
- Damien Conover
Pfizer Posts Solid 4Q and Issues Strong 2018 Guidance Driven by Lower ...
Pfizer reported slightly higher-than-expected fourth-quarter results and issued 2018 tax-rate guidance 500 basis points below our expectations, which will likely lead to an increase in our fair value estimate relatively close to the current stock price. Pfizer’s largely flat total revenue in the quarter despite generic competition, combined with the likelihood it can retain most of the U.S. tax reform benefits, helps reinforce our wide moat rating for the firm. Pfizer’s core drugs (pneumoco...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.